New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: 25% in a year might be a little fast
Reduces the harmful effects of free radicals
They shoukd know once b12 levels are kept high on injections they need to stay high for your body to utilise it 12 months ago I mentioned to the nurse that gave me my 12th weekly B12 that I self inject weekly for then to be told my surgery refuse to give me any more injection so I'm on my own now
Conclusion: It seems that transgender stroke survivors bear a greater burden of modifiable lifestyle risk factors and socioeconomic vulnerabilities, underscoring the need for targeted public health strategies
